乳癌化疗新进展zhengzhouPPT.ppt

;Worldwide Top 5 cancer incidence in 2000;No. of new cancer cases in Asia in 1990;乳腺癌患者死亡率降低原因;不同年龄乳腺癌患者的化疗疗效; 激素受体状况与辅助化疗疗效 (EBCTCG. Lancet,1998, 351:1451-1467);淋巴结状态与辅助治疗(NSABP B16);淋巴结状态与辅助治疗(NSABP-20);腋窝淋巴结阴性患者术后辅助化疗指征;哪些患者需要术后辅助治疗？;最佳治疗方案是什么？;确定是否选择含蒽环类药方案的临床试验;含紫杉类药方案是否优于非紫杉类药方案？;CALGB 9344 辅助治疗研究Update 11/00 Henderson et al;;;;;;NSABP B-28 研究设计;NSABP B-28: ASCO 2003 w/ med. f/u 64 Months;Adjuvant Sequential Taxanes: Summary;剂量密度化疗;; C 9741-CALGB 9741 A Randomized Trial of Dose Dense vs. Conventionally Scheduled and Sequential vs. Concurrent Combination Chemotherapy as Post-Operative Adjuvant Treatment of Node-Positive Primary Breast Cancer;C 9741: Trial Design;q 2 wk (w/G-CSF);C 9741: Eligibility Criteria;C 9741: Endpoints;C 9741: Results;Multivariate Cox Proportional Hazards Model: DFS (N=1973);Disease-Free Survival by Density;Multivariate Cox Proportional Hazards Model: OS (N=1973);Overall Survival by Density;Summary (I)36 Months Median Follow-Up;Summary (II)36 Months Median Follow-Up;Summary (III);含多西紫杉醇方案是否优于非多西紫杉醇方案？;BCIRG 001 N+;;;TAC;TAC;根据淋巴结状态分层的无病生存;TAC;;;血液学毒性;非血液学毒性 Grade 3 or 4 with Incidence 1%;比较含多西紫杉醇与不含多西紫杉醇方案的疗效总结（BCIRG 001）;结论;紫杉类药物在乳腺癌辅助治疗中的作用;化疗与他莫昔芬的给药顺序？; 确定化疗内分泌治疗顺序的临床试验（SWOG Breast Cancer Intergroup Trial 0100） 1、 单用TAM：361例2、CAF＋TAM同时给药组：550例3、CAF与TAM序贯给药组：566例结果：单用、同时、序贯组病人8年无病生存率分别为55％、62％、67％；总生存率分别为67％、71％73％。徐兵河. 中国医学论坛报，2002年，28（28）：41版;结论;辅助治疗时间多长为好?;确定辅助化疗时间的关键性临床试验;确定他莫昔芬给药时间的临床试验（荟萃分析）(EBCTCG，Fisher et al, Jordan et al, Cummings et al. Maenpaa et al, Baum et al) ;乳腺癌辅助治疗共识（1）;乳腺癌辅助治疗共识（2）; THE GOOD NEWS THERE IS A HIGH PROBABILITY THAT OUR ABILITY TO ??INDIVIDUALIZE?? CHEMOTHERAPY REGIMENS WILL MARKEDLY IMPROVE IN THE FUTURE ! ;GENE EXPRESSION PROFILING PREDICTS CLINICAL OUTCOME OF B.C. (Nature 2002);WE CAN IDENTIFY WHO BENEFITS MOST FROM TAXOL/FAC ADJUVANT THERAPY;晚期乳腺癌的化学治疗;乳腺癌;首次复发部位;晚期乳腺癌的化疗;Treatment of Metastatic Breast Cancer ;乳腺癌化疗新药;;晚期乳腺癌的联合化疗;TAX 303 疗效结果;CUT-OFF DATE : 15SEP97;